AlphAIalphai — Financial news for AI agents
fool.comAUG 202 min read$USIO

Usio (USIO) Q2 2026 Earnings Call Transcript

Usio (USIO) reported Q2 2026 revenue of $23.7M, up 19%, with net income of $280K. Key growth areas include credit card (28%) and ACH (21%). The company raised fiscal 2026 revenue guidance to 14-16% growth. Management highlighted PayFac's 43% growth and upcoming Usio Ion platform rollout, expected to increase daily cash float to $300M.

Original reporting
fool.com
Published Aug 20, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Usio (USIO) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$USIOBullishMed
01

Why it matters

Earnings beat and raised guidance likely trigger buying pressure; watch for volume on post‑market trading.

02

Market read

Usio's earnings beat and guidance raise present a short‑term trading opportunity in the fintech space.

03

What to watch

Rising interest‑rate environment could compress margins on real‑time payments.

Relevance 7/10Novelty 8/10Timing: post‑market release

Background

Usio (USIO) reported its Q2 2026 earnings, highlighting revenue growth, profitability, and an upgraded FY revenue outlook.

Company-level read

Ticker impact

$USIOBullishHigh confidence
Context

Q2 2026 earnings release with revenue of $23.7M (+19%) and updated FY guidance of 14-16% growth.

Expected impact

Potential short‑term price rally on earnings beat and guidance raise.

Evidence & confidence

First‑time disclosure of earnings and guidance; numbers exceed prior expectations and indicate accelerating growth.

Market effects

Sector

Strong growth in payment‑facilitation and ACH may benefit fintech peers.

Regional

U.S. fintech sector sees incremental demand from school‑voucher programs.

Global

Limited to U.S. fintech niche; minimal global spillover.

Counterpoint

What could challenge this read

Guidance may be optimistic given modest cash balance and competitive pressure.

Key entities

  • Executive
    Louis Hoch

    CEO who discussed growth drivers and real‑time payments.

  • Executive
    Greg Carter

    Chief Revenue Officer who outlined PayFac expansion.

Read at source← All news

Related articles

AUG 12
$USIOHigh

Usio, Inc. (USIO): Results of Operations and Financial Condition

Usio, Inc. (USIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_973961.htm EXHIBIT 99.1 ex_973961.htm Exhibit 99.1 Usio Announces Second Quarter 2026 Financial Results Revenue, Earnings per Share, and Adjusted EBITDA 1 beat Consensus Estimates Revenue up 19% , Adjusted EBITDA 1 up 128% Raises Fiscal 2026 Revenue Guidance, Revenue

SEC EDGAR 8-K6 min
AUG 24
$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

insidermonkey.com3 min
AUG 24
$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.

yahoo.com3 min